CD8A and head and neck cancer: In addition, high numbers of peripheral CD8+ T-cells expressing differentiation markers and lacking CCR7 are associated with response to nivolumab in NSCLC patients [43] whereas the presence of CD8+CCR7+ T-cells in the peripheral blood has been demonstrated to associate with disease recurrences in patients with head and neck cancers [44].